Latest Information Update: 05 Jul 2007
At a glance
- Originator Eisai Co Ltd
- Class Neuroprotectants
- Mechanism of Action Nerve growth factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Peripheral nervous system diseases
Most Recent Events
- 27 Apr 2004 Preclinical trials in Amyotrophic lateral sclerosis in Japan (unspecified route)
- 27 Apr 2004 Preclinical trials in Spinal cord injuries in Japan (unspecified route)